Low energy internal atrial cardioversion in atrial fibrillation lasting more than a year

Pacing Clin Electrophysiol. 1999 Jan;22(1 Pt 2):243-6. doi: 10.1111/j.1540-8159.1999.tb00341.x.

Abstract

The aim of this study was to evaluate the efficacy of low energy internal atrial cardioversion in restoring sinus rhythm (SR) in patients with chronic atrial fibrillation (AF) persisting > 1 year. Fifteen patients with chronic AF lasting > 1 year (from 13-48 months, mean 24 +/- 13 months) were studied. R wave synchronized 3/3 ms biphasic shocks were delivered between right atrial and coronary sinus (left pulmonary artery in five patients) electrodes. Sedatives or anesthetics were administered only at the patient's request.

Results: Stable SR was restored in 14 (93%) of 15 patients after shocks with a mean leading edge voltage of 377 +/- 77 V (range 260-500) and a mean delivered energy of 7.3 +/- 3.4 J (range 2.6-12.9). The procedure was performed without anesthesia in 6 (40%) patients. All successfully cardioverted patients were treated with flecainide, sotalol, or amiodarone. During a follow up of 7.7 +/- 7.9 months (range 1-24) AF recurred in five (36%) patients. Three of five AF recurrences occurred within 3 days after conversion to SR.

Conclusion: Internal low energy atrial cardioversion is highly effective in restoring SR even in patients with AF lasting > 1 year. The long-term results from the standpoint of freedom from AF recurrences, are satisfactory, although additional antiarrhythmic treatment is required, particularly in the first days after conversion.

Publication types

  • Comparative Study

MeSH terms

  • Anti-Arrhythmia Agents / therapeutic use
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / therapy*
  • Cardiac Catheterization
  • Chronic Disease
  • Electric Countershock / methods*
  • Electric Impedance
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Heart Atria
  • Heart Rate
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Artery
  • Secondary Prevention
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents